[Temporary Announcement] Haichang Pharmaceutical: Announcement of Resolutions of the First Extraordinary Shareholders Meeting in 2025
Announcement number: 2025-031
Securities code: 834402 Securities abbreviation: Haichang Pharmaceutical Sponsoring broker: Shenwan Hongyuan underwriting and sponsoring
Zhejiang Haichang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the First Extraordinary Shareholders Meeting in 2025
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Meeting convening and attendance
(1) Meeting status
Meeting time: November 17, 2025
Meeting method: √On-site meeting □Electronic communication meeting
Conference Room 3, Zhejiang Haichang Pharmaceutical Co., Ltd., No. 36, Changshun Road, Bingang Industrial City, Yuhuan City, Zhejiang Province. Meeting voting method:
√On-site voting □Electronic communication voting
□Online voting □Other ways to vote
Meeting convener: Board of Directors
Conference host: Wang Xu
Explanation on the legality and compliance of the convening situation:
The convening, holding and resolution review procedures of this general meeting of shareholders complied with the provisions of the Company Law and other relevant laws, administrative regulations, departmental rules, normative documents and the Articles of Association. This meeting does not require approval from relevant departments or necessary procedures.
(2) Meeting attendance
A total of 4 shareholders attended and authorized to attend this shareholders' meeting, holding a total of 36,347,465 shares with voting rights, accounting for 84.30% of the company's total voting shares.
Announcement number: 2025-031
(3) Attendance of the company’s directors, supervisors and senior managers at the shareholders’ meeting
The company has 7 current directors and 7 non-voting directors;
The company has 3 serving supervisors and 3 people attending;
The person in charge of the company’s information disclosure affairs attended the meeting;
Other senior managers of the company attended the meeting
2. Proposal review status
(1) Consideration and approval of the "Proposal on the expected sales of products to the related party Luzhibao Pharmaceutical Co., Ltd. in 2025"
- Contents of the motion:
The company expects that the cumulative amount of products sold to Lu Zhibao Pharmaceutical Co., Ltd. in 2025 will not exceed 30 million yuan. For specific details, please refer to the "Announcement on Estimated Routine Related Transactions in 2025" (Announcement No.: 2025-029) disclosed by the company on the designated information disclosure platform of the National Small and Medium-sized Enterprise Share Transfer System (www.neeq.com.cn) on October 31, 2025.
- Proposal voting results:
The number of common shares agreed was 14,339,356, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstention shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Avoid voting situations
As a related party in this matter, Hokuriku Pharmaceutical holds 22,008,109 shares of the company and avoids voting.
3. Documents for reference
"Resolution of the First Extraordinary General Meeting of Shareholders of Zhejiang Haichang Pharmaceutical Co., Ltd. in 2025"
Board of Directors of Zhejiang Haichang Pharmaceutical Co., Ltd.
November 17, 2025